Equity Overview
Price & Market Data
Price: $3.02
Daily Change: $0.00 / 0.00%
Daily Range: $2.81 - $3.45
Market Cap: $28,331,662
Daily Volume: 155,342
Performance Metrics
1 Week: -9.31%
1 Month: -24.88%
3 Months: -29.77%
6 Months: -92.01%
1 Year: -80.26%
YTD: -29.77%
Company Details
Employees: 10
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.